文献速递心脑血管急症重症综合管理与镇静镇痛

自发性脑出血早期使用塞来昔布与死亡率降低相关

Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality.
PubMed 文献 · Neurocrit Care · 2024-05-15
一句话结论回顾性倾向匹配队列显示,自发性脑出血后5天内使用塞来昔布与1年死亡率降低相关(13.33% vs 17.77%,p=0.0124)。

该研究基于TriNetX多机构研究数据库回顾性查询自发性脑出血(sICH)患者,将5天内接受塞来昔布者(队列1)与未接受者(队列2)比较,经倾向评分匹配后每组833例。主要终点为sICH后1年内死亡,塞来昔布组显著低于未用组(13.33% vs 17.77%,p=0.0124);呼吸机依赖、气管切开、经皮内镜下胃造瘘置管、开颅术、深静脉血栓、肺栓塞、缺血性卒中、短暂性脑缺血发作、心肌梗死及癫痫风险均未显著增加。另对使用布洛芬(非选择性COX抑制剂)者分析,死亡率无显著差异。作者认为早期塞来昔布使用与sICH患者死亡率降低相关。

要点

  • 倾向评分匹配后每组833例,sICH后5天内使用塞来昔布者1年死亡率13.33%,未用者17.77%(p=0.0124)。
  • 塞来昔布组呼吸机依赖、气管切开、经皮内镜下胃造瘘置管、开颅术、深静脉血栓、肺栓塞、缺血性卒中、短暂性脑缺血发作、心肌梗死及癫痫风险均未显著增加。
  • 使用布洛芬(非选择性COX抑制剂)者与未使用者相比死亡率无显著差异。
  • 作者认为早期塞来昔布使用与sICH患者死亡率降低相关,COX-2作为神经保护靶点受到关注。

适用人群与场景

  • 自发性脑出血(sICH)患者,来自TriNetX多机构研究数据库的回顾性查询人群。
  • 队列1为sICH后5天内接受塞来昔布者,队列2为未接受塞来昔布者,经倾向评分匹配后每组833例。

处置流程与药物剂量

  • 塞来昔布:sICH后5天内使用(原文未写明剂量、给药途径、频次及疗程),与未使用塞来昔布者比较1年死亡率。

研究设计与关键结果

  • 研究类型:基于TriNetX多机构研究数据库的回顾性查询研究;经倾向评分匹配后每组833例。
  • 主要终点:sICH后1年内死亡,塞来昔布组13.33% vs 未用塞来昔布组17.77%(p=0.0124),塞来昔布组显著降低。
  • 次要终点:呼吸机依赖、气管切开、经皮内镜下胃造瘘置管、开颅术、深静脉血栓、肺栓塞、缺血性卒中、短暂性脑缺血发作、心肌梗死及癫痫风险,塞来昔布组较未用组均未显著增加。
  • 布洛芬分析:使用布洛芬(非选择性COX抑制剂)者与未使用者相比死亡率无显著差异。

证据类型、等级与局限

  • 证据类型:基于多机构研究数据库的回顾性队列研究;原文未给出证据等级或推荐强度。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论为早期塞来昔布使用与sICH患者死亡率降低相关,COX-2作为sICH神经保护潜在靶点受到关注,但原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhagic strokes constitute 10-15% of all strokes and have the worst mortality and morbidity of all subtypes. Mortality and morbidity of spontaneous intracerebral hemorrhage (sICH) are often secondary to the effects of inflammation, brain edema, and swelling. Studies have shown that celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, reduces perihematomal edema formation and inflammation. This study aimed to examine the impact of celecoxib on sICH outcomes.

METHODS: TriNetX, a multi-institutional research database, was retrospectively queried to identify patients with sICH. Outcomes in patients who received celecoxib within 5 days (cohort 1) were analyzed and compared to those in patients who did not receive celecoxib (cohort 2). The primary end point was mortality within 1 year of sICH. Secondary end points included ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures. Further analysis was performed to assess these outcomes for patients treated with ibuprofen, a nonselective COX inhibitor.

RESULTS: After propensity score matching, 833 patients were identified in each cohort based on celecoxib use. Mortality at 1 year was significantly reduced in patients with sICH receiving celecoxib compared to those who did not (13.33% vs. 17.77%; p = 0.0124). Risks of ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures were not significantly increased in patients who received celecoxib within 5 days of sICH compared to those who did not receive celecoxib. There was no significant difference in mortality between patients based on ibuprofen administration.

CONCLUSIONS: There exists a growing interest in using COX-2 as a potential target strategy for neuroprotection in patients with sICH, with some evidence of a mortality benefit in small cohort studies. This study shows that early celecoxib use is associated with decreased mortality in patients with sICH.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Sciscent BY, Hallan DR, Bhanja D, et al. Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality. Neurocrit Care. 2024. PMID: 38750392. doi:10.1007/s12028-024-01996-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。